CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: GlobeNewswire
Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payment to CytomX Clinical Studies for CX-2009 and CX-072 impacted by Global COVID-19 Pandemic, Prompting Pipeline Reprioritization Conference Call Today, Monday March 30th at 6:00 p.m. ET/ 3:00 p.m. PT SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the achievement of a clinical milestone in conjunction with the CX-2029 program, triggering a $40 million payment from AbbVie to CytomX. The company also provided an update on its lead wholly owned clinical programs. “CytomX has made excellent progress during 2020, including the establishment of a major new strategic alliance with Astellas,
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceGlobeNewswire
- Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
CTMX
Earnings
- 11/7/24 - Beat
CTMX
Analyst Actions
- 11/11/24 - HC Wainwright
CTMX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- CTMX's page on the SEC website